Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.84 |
| ▸ | FAP | Q12884 | 6/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.84 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.84 |
| ▸ | HRH2 | P25021 | 1/20 | 0.84 |
| ▸ | MC4R | P32245 | 1/20 | 0.84 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.84 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.84 |
| ▸ | GHSR | Q92847 | 1/20 | 0.84 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17124942 | 1.00 | DPP4 (0.84) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL18624007 | 1.00 | DPP4 (0.84) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL12601330 | 0.92 | DPP4 (0.72) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL28983978 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL160188 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL17124941 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL195962 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL637238 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL29359185 | 0.92 | DPP4 (1.00) | DPP4FAPCHRM1POU2F2ADORA3 | |
| Linagliptin SCHEMBL16467827 | 0.91 | DPP4 (0.98) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185291-A1 | PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2018-07-05 | — | — | US | disclosed |
| US-20170095424-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | ALAPATI MOHAN MURALI (IN) | 2017-03-16 | — | — | US | disclosed |
| US-9555001-B2 | Pharmaceutical composition and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-01-31 | — | — | US | disclosed |
| US-9522915-B2 | Method for preparing an important intermediate of linagliptin | 2Y-CHEM, LTD. (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20160235680-A1 | PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2016-08-18 | — | — | US | disclosed |
| US-9212183-B2 | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | 2Y-CHEM, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-9056112-B2 | Process for preparation of pure linagliptin | DR. REDDY'S LABORATORIES LIMITED (IN) | 2015-06-16 | — | — | US | disclosed |
| US-8865729-B2 | Salt forms of a xanthine compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140303194-A1 | SALT FORMS OF ORGANIC COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20130236543-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120129874-A1 | SALT FORMS OF ORGANIC COMPOUND | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038889-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 365/4885CHRM1 2708/4885 |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | DPP4 10/4885FAP 882/4885CHRM1 2943/4885 |
| US-20170073345-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES AND PRE-DIABETES | DPP4, SLC5A1, SLC5A2 | DPP4 1/4885FAP 127/4885CHRM1 2286/4885 |
| US-20140303194-A1 | SALT FORMS OF ORGANIC COMPOUND | DPP4, DPP7, DPP3 | DPP4 1/4885FAP 484/4885CHRM1 4544/4885 |
| US-20160235680-A1 | PHARMACEUTICAL COMPOSITIONS | DPP4, SLC5A2, SLC5A1 | DPP4 1/4885FAP 143/4885CHRM1 4038/4885 |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | DPP4, DPP9, DPP3 | DPP4 1/4885FAP 19/4885CHRM1 4661/4885 |
| US-20130236543-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | DPP4, SLC5A2, SLC5A1 | DPP4 1/4885FAP 87/4885CHRM1 3761/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 366/4885CHRM1 3433/4885 |
| US-20140051714-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, DPP4 | DPP4 3/4885FAP 416/4885CHRM1 3217/4885 |
| US-20180185291-A1 | PHARMACEUTICAL COMPOSITIONS | DPP4, SLC5A2, SLC5A1 | DPP4 1/4885FAP 143/4885CHRM1 4038/4885 |
| US-20120129874-A1 | SALT FORMS OF ORGANIC COMPOUND | DPP4, DPP7, DPP8 | DPP4 1/4885FAP 720/4885CHRM1 2735/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885FAP 939/4885CHRM1 3279/4885 |
| US-20170095424-A1 | PHARMACEUTICAL COMPOSITION AND USES THEREOF | DPP4, SLC5A2, SLC5A1 | DPP4 1/4885FAP 87/4885CHRM1 3761/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | DPP4 9/4885FAP 799/4885CHRM1 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.